CERS

Cerus Corporation

NASDAQ

Add Alert

CERS

Cerus Corporation

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

03/19/24 9:05 AM

Post #328

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Awl416

03/19/24 8:34 AM

Post #327

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Monksdream PremiumMember

10/09/23 6:02 AM

Post #326

CERS new 52 week low

BottomBounce Free

01/01/21 11:35 PM

Post #325

Re: #324: @mogman - Looks like CP using Intercept plasma will push

$CERS Book Value Per Share (mrq) ONLY $0.65

mogman

08/23/20 10:09 PM

Post #324

Looks like CP using Intercept plasma will push the SP well over $7 and just could go over $20 if key metrics indicate a possible buy out. Since the closest competition Mirasol is now a non-starter with the FDA last week, CERS occupies a monopoly position. That is not to mention RBS approval in the next few years as well as the now released info that American Red Cross will not guarantee requested shipment fulfillment if Intercept is not stipulated. CERS now owns the market along with locked in distributors throughout the world. No brainer investment for the whole next decade. Even buying at $20 SP will be a 10 bagger in5 yeas or less. Probably less. Very long here.

Porterhouse10 Free

05/12/20 10:46 AM

Post #323

Looking for entry, awesome growth and balance sheet, could be a good Covid play jmo

ClayTrader Free

02/13/20 4:17 PM

Post #322

* * $CERS Video Chart 02-13-2020 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

02/04/20 5:28 PM

Post #321

* * $CERS Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

06/29/19 3:31 PM

Post #320

* * $CERS Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

TrendTrade2016 PremiumMember

05/14/18 6:07 AM

Post #319

CERS been in this play for 2 months now...time to make some noise!!!

cottonmather Free

03/12/18 1:48 PM

Post #318

Longer term technical promise. http://stockcharts.com/public/1164099

mogman

03/10/18 11:52 AM

Post #317

From Berkshire Hathaway's - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Recent developments and highlights include:

*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a

17% to 22% increase over 2017 reported product revenue.

*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.

IMO it is up from here and a buy at $5.

mogman

02/20/18 1:24 PM

Post #316

NAVY Department worth more than today's 4 cent CERS SP rise. Description: Department of the Navy

Bureau of Medicine and Surgery

U.S. Naval Hospital Guam

US Naval Hospital Guam intends to award a sole-source drop-shipment contract under the authority of FAR 13, due to the only source available to meet the Government's needs, to Cerus Corporation, 2550 Stanwell Drive, Concord, CA 94520. Reference NAICS Code 325412. The following products will be procured: 0001. INTERCEPT Platelet Small Volume Processing Set, P/N INT2110B. Quantity: 8 Cases (2 cases to be delivered on March 2018, May 2018, July 2018, and Sep 2018). 0002. INTERCEPT Platelet Processing Set with Dual Storage Containers, P/N INT2510B. Quantity: 5 Cases (2 cases to be delivered on March 2018, 1 case to be delivered on May 2018, July 2018, and Sep 2018. This notice of intent is not a request for competitive proposals.

FULL INFO https://www.fbo.gov/spg/DON/BUMED/N68096/N6809618Q0008/listing.html

Time for a big thumbs up on that start!!

StockRacer87 Free

01/24/18 6:03 PM

Post #315

Shorts attacked it well today

QuidRunner Free

01/24/18 9:19 AM

Post #314

Good new out yesterday after regarding CERS trials. Stock is steadily moving UP!!!

lugan

01/08/18 2:02 PM

Post #313

Re: #310: @jonnyvs - Is this today's bio play?

Yesterday, today and tomorrow!

ClayTrader Free

11/03/17 5:03 PM

Post #312

* * $CERS Video Chart 11-03-17 * *

Link to Video - click here to watch the technical chart video

Marvy

10/31/17 8:34 AM

Post #311

Big news!!!

jonnyvs

10/05/17 8:53 AM

Post #310

Is this today's bio play?

ResearchDD Free

08/27/17 7:55 PM

Post #309

What a joke!!!!!!!!!!!!!!!!!!!!!!! Played the Zika! Pump and now Dump!!!

ClayTrader Free

08/08/17 5:21 PM

Post #308

* * $CERS Video Chart 08-08-17 * *

Link to Video - click here to watch the technical chart video

Marvy

08/08/17 11:56 AM

Post #307

Employee buying?

BigTony1

08/02/17 3:36 PM

Post #306

Re: #305: @Marvy - Are things turning around?

you have to wait till tomorrow...

Marvy

08/02/17 11:45 AM

Post #305

Are things turning around?

ClayTrader Free

07/27/17 4:28 PM

Post #304

* * $CERS Video Chart 07-27-17 * *

Link to Video - click here to watch the technical chart video

Awesome A

07/01/17 8:47 PM

Post #303

The frustrating thing with this stock is whenever there is good news (as we had recently) the increase in the stock price is de minimis. However, whenever there is the hint of bad news, the stock price falls through the floor.

When is the red blood cell treatment going to be ready for FDA approval? There has been far too many delays on this and right now this stock needs to show profits (forget about narrowing losses). Also, any news if this company is the target of a merger or takeover?

ClayTrader Free

06/07/17 5:12 PM

Post #302

* * $CERS Video Chart 06-07-17 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

05/26/17 4:23 PM

Post #301

* * $CERS Video Chart 05-26-17 * *

Link to Video - click here to watch the technical chart video

mdimport

05/26/17 10:07 AM

Post #300

Re: #298: @kevinraugust25 - Every chart I see from the point the

I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.

Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."

starkd748

05/26/17 3:35 AM

Post #299

Re: #298: @kevinraugust25 - Every chart I see from the point the

Yea looks like that this one is done for awhile

kevinraugust25 Free

05/26/17 2:28 AM

Post #298

Re: #293: @starkd748 - Yea might buy to flip easy money this

Every chart I see from the point the stock starts falling to where it starts gaining steam again is 2-4 months... but mainly 2-3 months... now it may take 6 months to gain the ground it lost back.. but the bottom is around 2-3 months....

willlbone

05/25/17 5:28 PM

Post #297

Re: #296: @mdimport - Even with the oversold RSI? I was watching

Check the monthly charts. Every downtrend took about 6 months.

mdimport

05/25/17 5:22 PM

Post #296

Re: #295: @willlbone - Price will drift downward for 6 months, then buy.

Even with the oversold RSI? I was watching to see when there'd be a turn in the price and sentiment short-term.

Longer-term, I agree based on the announced delays.

Thanks for the inputs :)

willlbone

05/25/17 5:20 PM

Post #295

Re: #294: @mdimport - Do you see this company recovering?

Price will drift downward for 6 months, then buy.

mdimport

05/25/17 3:43 PM

Post #294

Re: #292: @willlbone - Heading under $2.

Do you see this company recovering?

starkd748

05/23/17 12:54 PM

Post #293

Re: #292: @willlbone - Heading under $2.

Yea might buy to flip easy money this thing has a ways to go....fda acting the same as ever lol

willlbone

05/23/17 12:33 PM

Post #292

Heading under $2.

wiltonio

05/08/17 10:39 AM

Post #291

Elk Creek Partners, LLC has filed a new 13G, reporting 5.17% ownership in $CERS - https://fintel.io/so/us/cers

starkd748

05/05/17 6:23 PM

Post #290

Re: #289: @ResearchDD - Waiting to buy CERS at 3.75 read my

Its lower. ..glad I sold went to penny mmj plays best move i could hsvr made

ResearchDD Free

05/03/17 4:34 PM

Post #289

Waiting to buy CERS at 3.75 read my post April 4

ResearchDD Free

04/04/17 3:17 PM

Post #288

I will buy back at 3.75 not highter

Harpo1

03/09/17 6:56 PM

Post #287

Re: #286: @Harpo1 - Hi Guys,

Hi Guys,

Looks like they took the recent earnings on the chin. And

bounced back.....This should run when if France, South Africa

launch and or FDA final goes into law.

Harpo1

03/08/17 2:42 PM

Post #286

Re: #285: @mogman - Noted.

Hi Guys,

Yes they are slow in marketing and sales. But this sell off will

reward much to those who hold for 2 plus years.

Action point.

FDA Blood safety guidelines issued for this year implementation

in 2018,

Sales of Incercept to France, Canada, Africa, and South America

mogman

03/06/17 10:55 AM

Post #285

Re: #283: @Harpo1 - Hi Guys,

Noted.

Harpo1

03/04/17 3:47 PM

Post #284

Re: #283: @Harpo1 - Hi Guys,

Hi Guys,

Looks like CERS issued some large bonus to key employees.

Looks bullish to me.

Earning after market closes on March 7, 2017.

Should test past highs!!!! And more. Several brokerage houses

have target prices $9-10.

With a lot more potential in the future!!!!

Harpo1

03/01/17 1:27 PM

Post #283

Re: #282: @mogman - Excerpts from

Hi Guys,

Really strange that CERS did not issue a press release with this detail study.

Something big must be up...........IMHO

Buying more here.

mogman

03/01/17 11:58 AM

Post #282

Re: #281: @Harpo1 - Hi Guys,

Excerpts from

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full
See full text for abbreviations and context.

Given their rapid emergence and lack of predictability,
emerging pathogens challenge the current testing paradigm...

An alternate way to manage the continuous threat of
emerging infectious agents is the use of PI technologies
to proactively protect the blood supply and mitigate the
risk of TTIDs. PI = Pathogen Inactivation

The findings of this study are of particular importance
after the US FDA recommended in August 2016 to
1) test all donations collected with a licensed or investigational
individual donor NAT for ZIKV under an investigational
new drug application, 2) to implement pathogen reduction
technology for PLTs and plasma using FDA-approved
devices, or 3) to implement pathogen reduction technology
for whole blood or RBCs if an FDA-approved or
investigational device becomes available.

The amotosalen/UVA systems for plasma and PLTs were
approved by FDA in 2014 and were commercially available
when ZIKV emerged in the Americas and the INTERCEPT
Blood System for PLTs was implemented at the time of the
ZIKV crisis in Puerto Rico in February 2016 to safeguard
and maintain the availability of the blood supply on the island.[60]

The results of this study complement previous results[65]
and show that ZIKV can be inactivated in all blood components
(Table 3) using amotosalen/UVA for PLTs and plasma[41]
and S-303 and GSH for RBCs. The availability of broad spectrum
PI technologies for all blood components enables a new paradigm
for blood safety that can be used to maintain the ongoing
availability and safety of blood products in time of epidemics
with newly emerged and potentially susceptible pathogens.

A great reason to buy while the price is at the $4 mark.... but not for long!!

Harpo1

03/01/17 11:04 AM

Post #281

Re: #280: @basssque - No idea on a timeline. I've been day

Hi Guys,

When this hit the wires we should see a good move upward.

http://onlinelibrary.wiley.com/doi/10.1111/trf.13993/full

Intercept tested on Zika infested blood; And removes from Red Blood Cells!!!!

basssque

01/30/17 4:33 PM

Post #280

Re: #279: @Awesome A - I am long on this stock and will

No idea on a timeline. I've been day trading it for the past week or so. Movement has been pretty predictable between the teens and twenties.

Awesome A

01/29/17 5:02 PM

Post #279

I am long on this stock and will continue to hold - but it is frustrating that good news does not seem to move the stock up - and the slightest amount of bad news brings the price down precipitously.

This company needs to start generating profits - sooner rather than later - and the only thing that will move them toward profitability is getting their red blood cell treatment approved by the FDA. Any time frame for getting this accomplished? If this is not done soon, we may be at a depressed stock price for many years into the future.

Older

Cerus Corporation (CERS)

Followers	42	Posters	67
Posts (Today)	0	Posts (Total)	328
Created	05/30/09	Type	Free
Moderators

http://www.cerus.com/

http://finance.yahoo.com/q/ks?s=CERS+Key+Statistics

Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company's INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. Cerus Corporation has collaboration agreements with Baxter International, Inc.; and BioOne Corporation, as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.